Acne affected 9.1% of the global population in a recent year. Up to 85% of adolescents and young adults experience this condition, which can cause significant psychosocial harm and demands considerable healthcare resources.
Key Takeaways
- 9.1% of people worldwide had acne in 2019
- Acne vulgaris is reported to affect up to 85% of adolescents and young adults
- Acne severity is commonly categorized into mild, moderate, and severe; severe acne can lead to significant psychosocial impairment
- Acne is a leading cause of skin-related outpatient visits in multiple countries, with substantial demand for dermatology care
- Dermatology visits for acne are common among outpatient populations in the US, with acne frequently appearing among top skin diagnoses
- In the UK, acne is among the most prevalent skin conditions, driving large numbers of primary care consultations
- The global acne treatment market is forecast to grow at a CAGR of about 6.0% from 2024 to 2030
- US sales of prescription acne drugs were estimated at roughly $1.5–$2.0 billion annually in the late 2010s
- Biologic and device-based acne therapies (where used) can carry higher per-course costs compared with conventional topical therapies
- A systematic review found that acne has a measurable negative effect on quality of life, including social and emotional domains
- Healthcare costs increase with acne severity, with more severe acne associated with higher utilization and treatment intensity
- A randomized trial reported that adapalene 0.1% gel achieved significant reductions in inflammatory and non-inflammatory lesions by 12 weeks
- A meta-analysis found that oral antibiotics reduce inflammatory lesion counts in acne over 8–12 weeks
- A network meta-analysis reported that different active treatments vary in effect sizes for inflammatory lesions, with some regimens outperforming others
- Over the 2022–2024 period, topical acne treatments increasingly include novel delivery systems (e.g., foams, gels, and combination fixed-dose products) to improve tolerability
Acne affects 9.1% worldwide and drives major healthcare costs, with effective treatments often requiring time and adherence.
Related reading
01 · Category
Disease Burden4 stats
01
9.1% of people worldwide had acne in 2019
02
Acne vulgaris is reported to affect up to 85% of adolescents and young adults
03
Acne severity is commonly categorized into mild, moderate, and severe; severe acne can lead to significant psychosocial impairment
04
In a global burden analysis, acne accounted for 0.11% of global years lived with disability (YLDs) in 2019
Interpretation
Disease Burden Interpretation
From a disease burden perspective, acne affected 9.1% of people worldwide in 2019 and still contributed to 0.11% of global years lived with disability, showing that a very common condition can generate measurable long-term impacts even when it is often discussed as a temporary skin issue.
02 · Category
Healthcare Utilization6 stats
01
Acne is a leading cause of skin-related outpatient visits in multiple countries, with substantial demand for dermatology care
02
Dermatology visits for acne are common among outpatient populations in the US, with acne frequently appearing among top skin diagnoses
03
In the UK, acne is among the most prevalent skin conditions, driving large numbers of primary care consultations
04
In a US employer-sponsored claims analysis, acne comprised about 1–2% of dermatology-related outpatient visits
05
In the US, the prevalence of acne among young people is high, and many seek medical care for persistent symptoms
06
Acne treatment often requires multiple lines of therapy over time, contributing to ongoing outpatient care needs
Interpretation
Healthcare Utilization Interpretation
Across multiple countries, acne drives sustained healthcare utilization, such as accounting for roughly 1 to 2 percent of dermatology outpatient visits in a US employer claims analysis and repeatedly ranking among the most common reasons for outpatient skin care.
03 · Category
Market Size2 stats
01
The global acne treatment market is forecast to grow at a CAGR of about 6.0% from 2024 to 2030
02
US sales of prescription acne drugs were estimated at roughly $1.5–$2.0 billion annually in the late 2010s
Interpretation
Market Size Interpretation
The market size for acne treatment is expanding steadily with a projected 6.0% CAGR from 2024 to 2030 and US prescription acne drug sales still reaching about $1.5 to $2.0 billion annually in the late 2010s.
More related reading
04 · Category
Cost Analysis11 stats
01
Biologic and device-based acne therapies (where used) can carry higher per-course costs compared with conventional topical therapies
02
A systematic review found that acne has a measurable negative effect on quality of life, including social and emotional domains
03
Healthcare costs increase with acne severity, with more severe acne associated with higher utilization and treatment intensity
04
Prescription acne medication costs can be a major share of direct treatment spending for moderate-to-severe cases
05
Economic analyses report that managing acne-related sequelae (e.g., scarring) can add substantial downstream costs
06
Patient-reported out-of-pocket spending for acne treatments can be significant, particularly for ongoing topical regimens
07
Topical combination products can reduce overall medication burden by consolidating multiple actives into single formulations
08
Adverse events (e.g., irritation from topical actives) can increase cost via treatment changes and management of skin side effects
09
Nonadherence to acne therapy is common and can increase downstream costs due to persistent disease and repeated visits
10
Quality-adjusted life-year (QALY) analyses in acne-related interventions often show that effective therapy can be cost-effective relative to standard care
11
Prescription drug price and reimbursement differences influence utilization patterns for acne treatments across payers
Interpretation
Cost Analysis Interpretation
Cost analysis shows that acne becomes increasingly expensive as severity rises, with moderate to severe cases often driven by prescription medication spending and even downstream costs for sequelae like scarring, while patients can also face significant ongoing out of pocket costs for topical regimens.
05 · Category
Clinical Effectiveness8 stats
01
A randomized trial reported that adapalene 0.1% gel achieved significant reductions in inflammatory and non-inflammatory lesions by 12 weeks
02
A meta-analysis found that oral antibiotics reduce inflammatory lesion counts in acne over 8–12 weeks
03
A network meta-analysis reported that different active treatments vary in effect sizes for inflammatory lesions, with some regimens outperforming others
04
Isotretinoin is associated with high long-term remission rates in severe acne; many patients maintain remission after a course
05
Randomized evidence supports that hormonal therapy (for women with acne) can reduce acne lesion counts
06
Laser and light therapies can produce improvements in inflammatory acne lesion counts, but results vary by device and protocol
07
Topical retinoids commonly require 8–12 weeks to show noticeable improvement in acne lesions
08
Adherence and tolerability are key predictors of acne outcomes, influencing effectiveness in real-world settings
Interpretation
Clinical Effectiveness Interpretation
Across randomized trials and meta-analyses under Clinical Effectiveness, acne treatments commonly show meaningful lesion reductions within about 8 to 12 weeks, with options ranging from adalapene 0.1% and oral antibiotics to isotretinoin’s high long-term remission rates in severe cases.
06 · Category
Industry Trends7 stats
01
Over the 2022–2024 period, topical acne treatments increasingly include novel delivery systems (e.g., foams, gels, and combination fixed-dose products) to improve tolerability
02
Dermatology telemedicine utilization expanded rapidly during 2020–2022, increasing remote access to acne care in many healthcare systems
03
Anti-inflammatory approaches beyond antibiotics and retinoids are a key emerging direction in acne therapeutics
04
Pharmacovigilance and safety programs are especially important for systemic retinoids like isotretinoin due to teratogenicity risk
05
Regulatory actions and label updates continue to shape acne treatment access and prescribing practices
06
Stewardship efforts reduce reliance on topical and oral antibiotics by increasing use of benzoyl peroxide and retinoid-based regimens
07
The burden of acne includes substantial indirect costs from reduced productivity and quality-of-life impacts
Interpretation
Industry Trends Interpretation
From 2020 to 2022, acne care moved faster on both the access side and the product side as telemedicine expanded rapidly and, over 2022 to 2024, topical treatments increasingly adopted novel delivery systems like foams and gels, underscoring the “Industry Trends” shift toward more innovative and reachable acne management.
report visual · Comparison
How common acne is (global and clinical context)
Acne affects a sizable share of people worldwide, with prevalence estimates reaching up to the adolescent/young adult range.
Acne vulgaris is reported to affect up to 85% of adolescents and young adults85%
9.1% of people worldwide had acne in 2019
9.1%
In a US employer-sponsored claims analysis, acne comprised about 1–2% of dermatology-related outpatient visits
2%
In a global burden analysis, acne accounted for 0.11% of global years lived with disability (YLDs) in 2019
0.11%
source-verifiedncbi.nlm.nih.gov · jamanetwork.com · thelancet.com2019
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
David Kowalski. (2026, February 13). Acne Statistics. Gitnux. https://gitnux.org/acne-statistics
MLA
David Kowalski. "Acne Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/acne-statistics.
Chicago
David Kowalski. 2026. "Acne Statistics." Gitnux. https://gitnux.org/acne-statistics.
Sources & references
38 datasets cited across this report · attribution is report-level
+28 additional datasets cited (not shown individually)